How to Get Evenity (Romosozumab) in South Carolina

What Romosozumab Is and Why It Matters for SC Patients

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates osteoblast-mediated bone building and reduces osteoclast-driven resorption, a dual mechanism unique among osteoporosis therapies [1]. The FDA approved Evenity in April 2019 for postmenopausal women at high risk of fracture [2].

South Carolina ranks among the states with the highest rates of osteoporotic hip fractures in adults over 65, according to CDC surveillance data on fall-related injuries [3]. For patients who have already fractured or whose T-scores fall at or below −2.5 despite prior antiresorptive therapy, romosozumab offers a time-limited anabolic treatment window. The 12-month course is typically followed by transition to an antiresorptive agent such as denosumab or a bisphosphonate to maintain gains in bone mineral density [4].

Access in South Carolina follows the same general pathway as other states. You need a qualifying diagnosis, a willing prescriber, successful prior authorization, and a specialty pharmacy that can dispense or ship the medication to you.

Prescriber Requirements in South Carolina

Any licensed physician (MD or DO) in South Carolina can prescribe Evenity. Nurse practitioners and physician assistants can also prescribe it under their respective collaborative practice agreements as defined by the SC Board of Medical Examiners. SC law requires NPs to maintain a written collaborative agreement with a physician, though it does not require the collaborating physician to co-sign each prescription [5].

Endocrinologists and rheumatologists prescribe romosozumab most frequently, but primary care physicians comfortable with osteoporosis management may also initiate therapy. The Endocrine Society's 2020 guidelines recommend anabolic-first therapy for patients at very high fracture risk, defined as a recent vertebral fracture, T-score ≤ −3.0, or a FRAX major osteoporotic fracture probability exceeding 30% [6].

Telehealth prescribing is legal in South Carolina. The SC Board of Medical Examiners permits the establishment of a physician-patient relationship via telemedicine, and the state does not impose a separate in-person visit requirement before prescribing [7]. This means a patient in Greenville, Charleston, or rural Oconee County can consult a bone health specialist remotely and receive a valid Evenity prescription.

Required Labs and Screening Before Starting

Before prescribing romosozumab, your provider will order specific diagnostic and safety labs. The Evenity prescribing information carries a boxed warning: romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death [2]. Prescribers should not initiate therapy in patients who have had a myocardial infarction or stroke within the preceding 12 months.

Standard pre-treatment workup includes:

• DEXA scan confirming a T-score of −2.5 or lower at the lumbar spine, femoral neck, or total hip, or documentation of a fragility fracture [8]
• Serum calcium to rule out hypocalcemia, which must be corrected before starting treatment [2]
• 25-hydroxyvitamin D level, with repletion to ≥30 ng/mL recommended by the Endocrine Society [9]
• Basic metabolic panel including creatinine and eGFR
• Cardiovascular risk assessment using ACC/AHA pooled cohort equations or clinical history review [10]
• CBC and alkaline phosphatase as baseline bone turnover markers

The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone. Romosozumab reduced new vertebral fractures by 48% at 24 months, but the romosozumab group showed a numerical imbalance in adjudicated serious cardiovascular events (2.5% vs. 1.9%) [1]. This imbalance informed the boxed warning and makes cardiovascular screening a non-negotiable step.

Prior Authorization: What SC Insurers Require

Prior authorization is the most common barrier to Evenity access. Expect it from every commercial insurer, Medicare Advantage plan, and Medicare Part B. The documentation package typically includes:

1. DEXA scan results showing a qualifying T-score (≤ −2.5) or evidence of fragility fracture confirmed by imaging
2. Fracture history or FRAX score supporting "high fracture risk" classification
3. Prior therapy documentation showing inadequate response to or intolerance of bisphosphonates (required by many, not all, plans)
4. Cardiovascular clearance noting the absence of MI or stroke in the past year
5. Prescriber attestation that the patient has been informed of cardiovascular risks

Medicare Part B covers Evenity under the "incident to" billing pathway when administered in a physician's office [11]. The J-code for romosozumab is J3111. Most Medicare Administrative Contractors in the Southeast require step-through documentation showing the patient meets the FDA-approved indication [12].

South Carolina Medicaid does not cover Evenity as of 2026. Patients on SC Medicaid who meet clinical criteria may need to explore the Amgen Assist 360 patient assistance program or appeal through a Medicaid fair hearing process [13]. Amgen's co-pay assistance program can reduce out-of-pocket costs to as low as $5 per month for commercially insured patients, though Medicare beneficiaries are not eligible for manufacturer co-pay cards by federal law.

Specialty Pharmacy and Dispensing in South Carolina

Evenity is distributed exclusively through specialty pharmacies. It is not stocked at retail pharmacies like CVS or Walgreens. Each monthly dose consists of two prefilled syringes (105 mg each), administered as consecutive subcutaneous injections in the abdomen, thigh, or upper arm [2].

Several national specialty pharmacy networks serve South Carolina, including Optum Specialty, Accredo (Express Scripts), and CVS Specialty. Your insurer's benefit design typically determines which specialty pharmacy you must use. Some plans allow "buy and bill" through a physician's office, where the practice purchases the drug and administers it on-site, billing Medicare Part B or the commercial medical benefit directly.

South Carolina does license 503A compounding pharmacies under the SC Board of Pharmacy. However, romosozumab is a biologic (a monoclonal antibody produced in CHO cells), and compounding pharmacies cannot legally replicate biologic drugs [14]. There is no compounded alternative to Evenity. Any claim otherwise should raise immediate concern about product legitimacy.

Shipping timelines vary. Most specialty pharmacies deliver within 3 to 5 business days after prior authorization approval. Evenity must be refrigerated at 2°C to 8°C and shipped in cold-chain packaging [2]. Patients in rural parts of South Carolina should confirm that their delivery address can receive temperature-sensitive shipments reliably.

Cost and Financial Assistance Options

Evenity's wholesale acquisition cost exceeds $22,000 for a full 12-month course. Out-of-pocket costs depend entirely on insurance structure.

For commercially insured patients, Amgen's Evenity co-pay card may cover most of the patient responsibility, reducing costs to $5 per injection for eligible individuals [13]. Medicare Part B typically covers 80% of the allowable amount after the Part B deductible, leaving the patient responsible for the remaining 20%, which a Medigap plan may cover.

The AACE 2020 clinical practice guidelines note that cost and access barriers are a primary reason anabolic agents are underused, even in patients at very high fracture risk [15]. A 2021 analysis published in the Journal of Bone and Mineral Research found that only 8.5% of patients eligible for anabolic therapy actually received it within 12 months of a fragility fracture [16]. South Carolina's lack of Medicaid coverage for Evenity contributes to this treatment gap.

Patients without adequate coverage should ask their prescriber's office to submit a prior authorization appeal if initially denied. A 2022 study in Osteoporosis International found that 40% of initial denials for romosozumab were overturned on appeal when accompanied by detailed fracture risk documentation and a letter of medical necessity [17].

Transitioning After the 12-Month Course

Romosozumab is FDA-approved for a single 12-month course only. Bone mineral density gains begin to reverse within months of discontinuation if no antiresorptive follow-up is initiated [4]. The FRAME extension trial showed that patients who transitioned from romosozumab to denosumab continued gaining BMD at the total hip and lumbar spine through 36 months, while those switched to placebo lost the gains [18].

The recommended approach, supported by the Endocrine Society and AACE guidelines, is to transition to denosumab (Prolia, 60 mg subcutaneously every 6 months) or a bisphosphonate such as alendronate (70 mg weekly oral) immediately after completing the 12th romosozumab injection [6][15]. Do not leave a gap between the last romosozumab dose and the first antiresorptive dose.

For South Carolina patients, this transition requires a separate prior authorization for the follow-on drug. Denosumab also carries specialty pharmacy requirements and prior authorization. Planning the transition at month 9 or 10 of romosozumab therapy avoids lapses in treatment.

How Telehealth Works for Evenity Prescribing in SC

Telehealth removes geography as a barrier. A patient in Sumter, Orangeburg, or Myrtle Beach can see a bone health specialist based in Charleston or Columbia, or even out of state if the prescriber holds an active SC medical license or practices under an interstate compact.

South Carolina participates in the Interstate Medical Licensure Compact, which allows physicians licensed through the compact to practice telemedicine across member states [7]. During a telehealth visit, the prescriber reviews DEXA results (which can be obtained locally), lab work, fracture history, and cardiovascular risk. If criteria are met, the prescriber sends the Evenity prescription electronically to the designated specialty pharmacy and initiates prior authorization.

The first injection can be administered at a local physician's office, infusion center, or even by a home health nurse in some cases. Subsequent monthly injections follow the same pattern. Some patients learn self-injection, though the dual-syringe administration is more commonly performed by a healthcare professional [2].

A 2023 analysis in the Journal of Clinical Endocrinology and Metabolism found that telehealth-initiated osteoporosis treatment had equivalent 12-month adherence rates compared to in-person initiation, at 71% versus 68% [19]. For South Carolina residents in rural counties without nearby endocrinologists, telehealth may be the most practical path to romosozumab.

Cardiovascular Safety: What the Evidence Shows

The boxed warning on Evenity's label requires direct discussion. In the ARCH trial, adjudicated serious cardiovascular adverse events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over 12 months [1]. The absolute risk difference was 0.6%. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 18-1 in favor of approval despite this signal, concluding that the fracture reduction benefit outweighed the risk in the indicated population [20].

The FRAME trial (N=7,180), which compared romosozumab to placebo, did not show a cardiovascular imbalance (1.0% vs. 1.0% at 12 months) [18]. The discrepancy may relate to the ARCH comparator: alendronate itself may have mild cardioprotective effects, making the relative comparison less favorable for romosozumab.

For South Carolina prescribers, the practical takeaway is clear: screen every patient for cardiovascular risk factors, avoid prescribing within 12 months of MI or stroke, and document the risk-benefit discussion. Patients with diabetes, hypertension, hyperlipidemia, or smoking history need especially careful evaluation before initiation [10].